EJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide-based therapeutic agents for application in nuclear medicine and molecular imaging. The journal provides a platform for chemists, pharmacists, biologists and basic scientists to present their views and scientific work. In addition, the journal provides insight into novel concepts of imaging or radionuclide-based therapeutic agent applications of relevance for the whole molecular imaging community.
The journal reports original research articles, review papers, guidelines on the application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel production methods of radionuclides, novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To foster daily practice in the community the journal stimulates submission regarding best practice and harmonization of methodologies. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in the form of guidelines or position papers.
To further serve the community the journal publishes abstracts of radiopharmaceutical-oriented congresses.
2022 Citation Impact
4.6 - 2-year Impact Factor
4.4 - 5-year Impact Factor
1.534 - SNIP (Source Normalized Impact per Paper)
0.972 - SJR (SCImago Journal Rank)
2023 Speed
10 days submission to first editorial decision for all manuscripts (Median)
44 days submission to accept (Median)
2023 Usage
342,661 downloads
51 Altmetric mentions
